Drug application
LAMIVUDINE (LAMIVUDINE)
Drugs@FDA ANDA 202032 · AUROBINDO PHARMA LTD
Key facts
| Drug name | LAMIVUDINE |
|---|---|
| Active ingredients | LAMIVUDINE |
| Application type | ANDA |
| Application number | 202032 |
| Company | AUROBINDO PHARMA LTD |
| Dosage forms | TABLET, ORAL |
| Strength | 150MG |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Not Applicable |
| Latest submission status date | Nov 17, 2011 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
- No FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: